Business Description
Oncternal Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US40052B2079
Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 76.33 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 7.6 | |||||
| 3-Year FCF Growth Rate | 14.1 | |||||
| 3-Year Book Growth Rate | -39.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 22.36 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 26.79 | |||||
| 14-Day RSI | 26.79 | |||||
| 6-1 Month Momentum % | 6.4 | |||||
| 12-1 Month Momentum % | -0.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 2.39 | |||||
| Cash Ratio | 2.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 2.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -150.49 | |||||
| ROA % | -116.39 | |||||
| ROIC % | -1164.85 | |||||
| ROC (Joel Greenblatt) % | -16081.84 | |||||
| ROCE % | -152.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.17 | |||||
| Price-to-Tangible-Book | 0.17 | |||||
| EV-to-EBIT | 0.36 | |||||
| EV-to-EBITDA | 0.36 | |||||
| EV-to-Forward-Revenue | 0.5 | |||||
| EV-to-FCF | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.17 | |||||
| Price-to-Net-Cash | 0.19 | |||||
| Earnings Yield (Greenblatt) % | 277.78 | |||||
| FCF Yield % | -1708.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncternal Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.383 | ||
| Beta | 0 | ||
| Volatility % | 71.24 | ||
| 14-Day RSI | 26.79 | ||
| 14-Day ATR (€) | 0.000775 | ||
| 20-Day SMA (€) | 5.32 | ||
| 12-1 Month Momentum % | -0.75 | ||
| 52-Week Range (€) | 4.32 - 11.8 | ||
| Shares Outstanding (Mil) | 2.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncternal Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncternal Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncternal Therapeutics Inc Frequently Asked Questions
What is Oncternal Therapeutics Inc(FRA:GTU)'s stock price today?
The current price of FRA:GTU is €5.32. The 52 week high of FRA:GTU is €11.80 and 52 week low is €4.32.
When is next earnings date of Oncternal Therapeutics Inc(FRA:GTU)?
The next earnings date of Oncternal Therapeutics Inc(FRA:GTU) is 2025-03-07 Est..
Does Oncternal Therapeutics Inc(FRA:GTU) pay dividends? If so, how much?
Oncternal Therapeutics Inc(FRA:GTU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers